Bezlotoxumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Clostridioides difficile toxin B |
| Clinical data | |
| Trade names | Zinplava |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617003 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6464H9974N1726O2014S46 |
| Molar mass | 145565.72 g·mol−1 |
Bezlotoxumab, sold under the brand name Zinplava, is a human monoclonal antibody designed for the prevention of recurrence of Clostridioides difficile infections.[3][4] Bezlotoxumab binds to Clostridioides difficile toxin B.[3]
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
- ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
- ^ a b c "Zinplava- bezlotoxumab injection, solution". DailyMed. 26 May 2023. Retrieved 20 October 2024.
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council - Bezlotoxumab" (PDF). American Medical Association. Archived from the original on 16 September 2012. Retrieved 25 October 2012.